Drugs / Garsorasib
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07472478 | Mar 2026 → Dec 2027 expected | non-small cell lung carcinoma | Guangdong Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07294261 | Dec 2025 → Oct 2028 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07601048 Comparator | Jun 2026 → May 2028 expected | — | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Garsorasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07601048 ↗ |